Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Økonomisk Ugebrev Life Science Investor Forum (March 2020)
23 slides from Expres2ion Biotech Holding Ab's conference presentation, March 2020
Slide 1: healthier wo
healthier wo
Slide 2: Disclaimer
expreSceion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentat
Slide 3: Company overview
Company overview
Slide 4: About ExpreS2ion
expreSceion BIOTECH About ExpreS2ion a ExpreS2io n Biotech Holding AB ee a Expre. Biotechno _. S2ion logies ApS \ AdaptVac ApS NS ExpreS2ion Biotech Holding AB po + Listed on the Nasdaq First North Growth Market since 2016 + Holding company for ExpreS2ion Biotechnologies ApS, which it owns 100% 5 Ex
Slide 5: Management team
Management team Over 100 years of experience relevant to advancing drug development Bent Frandsen CEO >25 years industry, finance, business development and management experience MSc in Finance/Strategic Management Copenhagen Business School Jute AK & Colopast GALIC 6 AGC Biologics | nsgene Keith Ale
Slide 6: ExpreS2™ platform technology
ExpreS2™ platform technology 1) Enables development of novel vaccines ExpreS2-produced proteins can be combined with, e.g., a virus-like particle to produce vaccines 2) Enables production of hard-to-express proteins IN rN Advantages to other vaccine types 1. Safety — Inherently safe, as they cannot
Slide 7: ExpreS2 platform proofs-of-concept
ExpreS2 platform proofs-of-concept Influenza Through partnership with Copenhagen University Nipah and filovirus Through participation in VICI consortium Two undisclosed projects optimization Cytomegalovirus ExpreS2ion has first right to license Influenza Through participation in INDIGO consortium +
Slide 8: expreSceion
expreSceion BIOTECH Discovery Lead opt CTA-enabling Phi Ph2 Ph3. Market size ES2B-CO001 >€10 (therapeutic) ee bs ° ESZB-|002 Infectious >€2 @ Cytomegalovirus disease Billion? 5 8 (prevention) Exploratory >€2 Undisclosed Billion’ 1@10ba1 Dato, 2022, for HERD breast concer 2Morket estimate fiom Madero
Slide 9: 2020 2021 2022 2023 2024-2025
2020 2021 2022 2023 2024-2025
Slide 10: ES2B-C001
exp a/ at a iN, oF | ' ed ES2B-COO1 v
Slide 11: Breast Cancer is the most common cancer
expreSeion BIOTECH Breast Cancer is the most common cancer * 1in 8 women will be diagnosed with invasive breast cancer ¢ In approximately 25% of breast cancer tumours, HER2 is overexpressed, which is associated with a more aggressive disease, higher recurrence rate, and increased mortality’ ¢ 685,00
Slide 12: Competitive landscape leaves room for improvement
expreSeion Competitive landscape leaves room for improvement ar PERJETA pertuzumab Herceptin trastuzumab Monoclonal antibodies (mAbs) and chemotherapy Standard of care for most stage Il and Il HER2+ breast cancers after surgery! + mAbs target the HER2 receptor on tumour cells to reduce proliferation
Slide 13: ES2B-C001 could succeed where other HER2 vaccines are failing
expreSeion BIOTECH ES2B-CO0O1 could succeed where other HER2 vaccines are failing Solutions under development _Limitations Overcome by ES2B-COO Epit paced in * Limited to certain HLA subtypes v ale coca a achel Ve cara leas * Limited capacity to overcome therapy resistance v No clinical validation i
Slide 14: expreSeion
expreSeion BIOTECH ee : Description Benefits vs. commercial mAbs Indication in first see : Extracellular domain (ECD) of * Polyclonal antibodies generated breast cancer (BC) HER2 protein coupled to the by ES2B-CO001 target numerous Acinetobacter Phage 205 (AP205) epitopes within the ECD of HER2 caps
Slide 15: Overcomes Herceptin resistance
expreSeion BIOTECH Overcomes Herceptin resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence ES2B-C001 trastuzuma Both Herceptin (trastuzumab) and ES2B-C001 inhibited growth in the trastuzumab-sensitive cells Trastuzumab- sensitive HER2+ human cancer cells! On
Slide 16: Prevention of mammary Carcinoma
expreSceion BIOTECH Prevention of mammary Carcinoma In HER2 transgenic Delta 16 mice with a human candidate ES2B-CO01 **p<0.01 by the log-rank test 100 “ees ] —® Control n=12 x ‘ ES2B-CO001 10g + s ~*" PBS n=12 Vaccination with only2doses & ** __£S2B-C001 10g + I 50 ji = of adjuvanted ES2B-0001 5 ad
Slide 17: Tumor volume
Vehicle Vehicle Vehicle 10 g ES2B-C001 ES2B-C001 ES2B-C001 g 1010 g i.m.i.m. i.m. 10 g ES2B-C001 ES2B-C001 ES2B-C001 g 10 10 g i.m.+Montanide i.m.+Montanide i.m.+Montanide 2.5 bleeding administration bleeding administration bleeding administration Tumor volume (cm3) 2.0 Mean ± SEM 2.5 2.52.5 1
Slide 18: Status: rapidly approaching clinical readiness
expreSceion BIOTECH Status: rapidly approaching clinical readiness Preclinical safety * Study is complete * Draft report is near completion Chemistry, manufacturing and controls + GMP drug substance production initiated + Stability studies underway Clinical * Design of Phase | clinical trial underwa
Slide 19: Obtainable market estimated at €2.8 billion
expreSeion BIOTECH Obtainable market estimated at €2.8 billion Number of annual patients Total: 1,414,000 TAM: 1,098,696 Total market Number of treated breast cancer patients per year $32 billion global market size expected by 2026! Total addressable market In top 8 countries with early or advanced
Slide 20: Oncology scientific advisory board
expreSceion BIOTECH Oncology scientific advisory board Advised by the leading specialists in oncology and specifically breast cancer » Dr. Giuseppe Curigliano, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the Eu
Slide 21: Investment highlights
expreS2ion BIOTECH Investment highlights Unmet medical * ExpreS2ion is developing a therapy for HER2+ breast need cancer, the most common cancer * Obtainable market conservatively estimated at Market size €28B “pe broad mix of proprietary and partner-driven Bepeation vaccine candidates Experienced t
Slide 22: Q&A
Q&A
Slide 23: investor@
investor@ expreS2ion
ExpreS2ion Biotech Holding — Økonomisk Ugebrev Life Science Investor Forum (March 2020) on 6ix